Nuttall Jeremy P, Thake Daryl C, Lewis Mark G, Ferkany John W, Romano Joseph W, Mitchnick Mark A
International Partnership for Microbicides, 8401 Colesville Road, Suite 200, Silver Spring, MD 20910, USA.
Antimicrob Agents Chemother. 2008 Mar;52(3):909-14. doi: 10.1128/AAC.00330-07. Epub 2007 Dec 17.
Dapivirine is a nonnucleoside reverse transcriptase inhibitor being developed as a topical microbicide for the prevention of human immunodeficiency virus infection. The distribution of radioactivity and drug in plasma and in vaginal, cervical, and draining lymph node tissues was investigated after daily application of a vaginal gel formulation of [14C]dapivirine to rhesus macaques. This was preceded by a preliminary study with rabbits. Following the intravaginal administration of [14C]dapivirine ( approximately 0.1 mg/ml [15 microCi/ml]) to rabbits (0.5 ml/day) and macaques (1 ml/day) for 7 days, the dapivirine levels associated with vaginal and cervical tissue samples 1 h after the final dose were high (quantities of microg/g of tissue) and remained detectable at 24 h (mean, >or=2.5 ng/g in rabbits) and 48 h (mean, >80 ng/g in macaques). Radioactivity levels were low in the plasma and very low or unquantifiable in the draining lymph nodes of the macaques. Microautoradiography identified drug-related material (DRM) on the surfaces of the vaginal and cervical tissues of the rabbits and macaques. Although DRM was primarily associated with the outermost layer of shedding cells in rabbits, two animals showed some evidence of small quantities in the mucosal epithelium of the cervix. In macaques, DRM was seen within the keratinized layer of the vaginal epithelium and and was found to extend into the superficial cellular layers, and in at least one animal it appeared to be present in the deepest (germinal) layer of the epithelium and in submucosal tissues. The persistence of biologically significant concentrations of dapivirine in vaginal and cervical tissues for >24 h supports the development of dapivirine as a microbicide for once daily application.
达匹韦林是一种非核苷类逆转录酶抑制剂,正被开发用作预防人类免疫缺陷病毒感染的局部杀菌剂。在恒河猴每日应用[14C]达匹韦林阴道凝胶制剂后,研究了放射性和药物在血浆以及阴道、宫颈和引流淋巴结组织中的分布情况。在此之前,先对兔子进行了一项初步研究。给兔子(0.5毫升/天)和恒河猴(1毫升/天)阴道内给予[14C]达匹韦林(约0.1毫克/毫升[15微居里/毫升]),持续7天,最终剂量后1小时,与阴道和宫颈组织样本相关的达匹韦林水平很高(微克/克组织量),在24小时(兔子中平均≥2.5纳克/克)和48小时(恒河猴中平均>80纳克/克)仍可检测到。恒河猴血浆中的放射性水平较低,引流淋巴结中的放射性水平非常低或无法定量。显微放射自显影术在兔子和恒河猴的阴道和宫颈组织表面鉴定出了药物相关物质(DRM)。虽然DRM主要与兔子脱落细胞的最外层相关,但有两只动物的宫颈黏膜上皮有少量存在的迹象。在恒河猴中,DRM见于阴道上皮的角质化层内,并延伸至浅表细胞层,在至少一只动物中,它似乎存在于上皮的最深(生发)层和黏膜下组织中。达匹韦林在阴道和宫颈组织中具有生物学意义的浓度持续>24小时,这支持了将达匹韦林开发为每日应用一次的杀菌剂。